Two separate cell‑therapy advances surfaced: a first‑in‑human phase I study tested allogeneic iPSC‑derived invariant natural killer T (iNKT) cells in recurrent head and neck cancer, and Vigencell announced VT‑EBV‑N met its Phase II endpoint in natural killer T‑cell lymphoma. The iPSC‑iNKT program represents a push to scale off‑the‑shelf cellular immunotherapies, while Vigencell’s antigen‑specific killer T cells target an orphan, aggressive lymphoma with limited options. Vigencell said it will seek conditional approval in South Korea based on positive top‑line data and plans rapid regulatory and commercialization steps domestically and internationally. The iPSC‑iNKT data provide early safety and feasibility signals for a pluripotent stem cell‑derived immune cell platform that could reduce manufacturing complexity compared with autologous approaches. Together, these developments reflect dual industry strategies—personalized autologous cell products versus standardized allogeneic platforms—each raising questions about scalability, regulatory pathways and commercialization timelines as companies move toward pivotal testing and filings.